Anti‐infliximab antibody concentrations can guide treatment intensification in patients with Crohn's disease who lose clinical response

The presence of antibodies towards infliximab (ATI) is associated with lower infliximab (IFX) trough concentrations and loss of response. IFX treatment intensification is effective for restoring response in most, but not all patients with Crohn's disease (CD).

[1]  S. Vermeire,et al.  Clinical relevance of detecting anti-infliximab antibodies with a drug-tolerant assay: post hoc analysis of the TAXIT trial , 2017, Gut.

[2]  S. Vermeire,et al.  Immunoassay for Detection of Infliximab in Whole Blood Using a Fiber-Optic Surface Plasmon Resonance Biosensor. , 2017, Analytical chemistry.

[3]  S. Vermeire,et al.  DOP029 Clinical relevance of detecting anti-infliximab antibodies with a drug-tolerant assay: post-hoc analysis of the taxit trial. , 2017, Journal of Crohn's & colitis.

[4]  R. Eliakim,et al.  Addition of an immunomodulator can reverse antibody formation and loss of response in patients treated with adalimumab , 2017, Alimentary pharmacology & therapeutics.

[5]  S. Vermeire,et al.  Rapid Test for Infliximab Drug Concentration Allows Immediate Dose Adaptation , 2016, Clinical and translational gastroenterology.

[6]  A. Gonçalves,et al.  Proactive therapeutic drug monitoring of infliximab: a comparative study of a new point‐of‐care quantitative test with two established ELISA assays , 2016, Alimentary pharmacology & therapeutics.

[7]  S. Bonovas,et al.  Biologic Therapies and Risk of Infection and Malignancy in Patients With Inflammatory Bowel Disease: A Systematic Review and Network Meta-analysis. , 2016, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[8]  S. Vermeire,et al.  Pharmacokinetic Modeling and Simulation of Biologicals in Inflammatory Bowel Disease: The Dawning of a New Era for Personalized Treatment. , 2016, Current drug targets.

[9]  N. Ding,et al.  Systematic review: predicting and optimising response to anti‐TNF therapy in Crohn's disease – algorithm for practical management , 2016, Alimentary pharmacology & therapeutics.

[10]  A. Amiot,et al.  The outcome of infliximab dose doubling in 157 patients with ulcerative colitis after loss of response to infliximab , 2015, Alimentary pharmacology & therapeutics.

[11]  T. Matsui,et al.  Circulating Interleukin 6 and Albumin, and Infliximab Levels Are Good Predictors of Recovering Efficacy After Dose Escalation Infliximab Therapy in Patients with Loss of Response to Treatment for Crohn's Disease: A Prospective Clinical Trial , 2015, Inflammatory bowel diseases.

[12]  Els Brouwers,et al.  Generation of a Highly Specific Monoclonal Anti-Infliximab Antibody for Harmonization of TNF-Coated Infliximab Assays , 2015, Therapeutic drug monitoring.

[13]  K. Van Steen,et al.  Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. , 2015, Gastroenterology.

[14]  B. Sands,et al.  High-dose infliximab therapy in Crohn's disease: clinical experience, safety, and efficacy. , 2015, Journal of Crohn's & colitis.

[15]  L. A. Christensen,et al.  Changes in serum trough levels of infliximab during treatment intensification but not in anti-infliximab antibody detection are associated with clinical outcomes after therapeutic failure in Crohn's disease. , 2015, Journal of Crohn's & colitis.

[16]  T. Kitazono,et al.  Therapeutic Strategy for Crohn's Disease with a Loss of Response to Infliximab: A Single-Center Retrospective Study , 2015, Digestion.

[17]  A. Moss,et al.  Editorial: adalimumab dose escalation is effective for managing secondary loss of response in Crohn's disease , 2014, Alimentary pharmacology & therapeutics.

[18]  L. Dieleman,et al.  Adalimumab dose escalation is effective for managing secondary loss of response in Crohn's disease , 2014, Alimentary pharmacology & therapeutics.

[19]  M. Silverberg,et al.  Review article: a clinician's guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease , 2013, Alimentary pharmacology & therapeutics.

[20]  U. Kopylov,et al.  Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease. , 2013, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[21]  J. Gisbert,et al.  Doubling the infliximab dose versus halving the infusion intervals in Crohn's disease patients with loss of response , 2012, Inflammatory bowel diseases.

[22]  T. Matsui,et al.  Retrieval of Serum Infliximab Level by Shortening the Maintenance Infusion Interval Is Correlated with Clinical Efficacy in Crohn's Disease , 2012, Inflammatory bowel diseases.

[23]  J. Terdiman,et al.  Durability of Infliximab Dose Intensification in Crohn’s Disease , 2012, Digestive Diseases and Sciences.

[24]  J. Mate,et al.  Intensification of infliximab therapy in Crohn's disease: efficacy and safety. , 2012, Journal of Crohn's & colitis.

[25]  Leon Dent,et al.  Next-gen sequencing of multi-drug resistant Acinetobacter baumanii at Nashville General Hospital at Meharry , 2011, BMC Bioinformatics.

[26]  S. Ben-Horin,et al.  Review article: loss of response to anti‐TNF treatments in Crohn’s disease , 2011, Alimentary pharmacology & therapeutics.

[27]  Xavier Robin,et al.  pROC: an open-source package for R and S+ to analyze and compare ROC curves , 2011, BMC Bioinformatics.

[28]  U. Kopylov,et al.  The efficacy of shortening the dosing interval to once every six weeks in Crohn’s patients losing response to maintenance dose of infliximab , 2011, Alimentary pharmacology & therapeutics.

[29]  S. Schreiber,et al.  The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organization: When to Start, When to Stop, Which Drug to Choose, and How to Predict Response? , 2011, The American Journal of Gastroenterology.

[30]  Pedro M. Valero-Mora,et al.  ggplot2: Elegant Graphics for Data Analysis , 2010 .

[31]  W. Sandborn,et al.  Clinical Utility of Measuring Infliximab and Human Anti-Chimeric Antibody Concentrations in Patients With Inflammatory Bowel Disease , 2010, The American Journal of Gastroenterology.

[32]  Hadley Wickham,et al.  ggplot2 - Elegant Graphics for Data Analysis (2nd Edition) , 2017 .

[33]  J. Gisbert,et al.  Loss of Response and Requirement of Infliximab Dose Intensification in Crohn's Disease: A Review , 2009, The American Journal of Gastroenterology.

[34]  G. Kaplan,et al.  Infliximab dose escalation vs. initiation of adalimumab for loss of response in Crohn’s disease: a cost‐effectiveness analysis , 2007, Alimentary pharmacology & therapeutics.

[35]  P. Rutgeerts,et al.  Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn’s disease , 2007, Gut.

[36]  P. Rutgeerts,et al.  Infliximab maintenance therapy for fistulizing Crohn's disease. , 2004, The New England journal of medicine.

[37]  An Carbonez,et al.  Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. , 2003, The New England journal of medicine.

[38]  S. Hanauer,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[39]  B. Scallon,et al.  Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. , 1993, Molecular immunology.

[40]  John Fox,et al.  Robust Regression in R An Appendix to An R Companion to Applied Regression, Second Edition , 2011 .

[41]  Alan J. Miller,et al.  leaps: Regression Subset Selection. , 2004 .